NFE2L2 and cancer: Co-mutation of KRAS and KEAP1/NFE2L2 predicts worse survival to chemotherapy and immunotherapy (79), and Nrf-2-regulated ROS homeostasis has been linked to chemotherapy resistance in NSCLC and other cancers (76, 80–83).